Taysha Gene Therapies prices $200 million public offering

GlobeNewswire··Read original
3▲2 ▼1Impact / 5
Summary · why it matters

Taysha Gene Therapies has priced an underwritten public offering expected to generate approximately $200 million in gross proceeds. The offering includes 32,500,001 shares of common stock at $6.00 per share and pre-funded warrants to purchase 833,333 shares at $5.999 per warrant, before underwriting discounts and commissions. The underwriters have a 30-day option to purchase up to an additional 5,000,000 shares of common stock. Jefferies, Goldman Sachs & Co. LLC, Piper Sandler and Cantor are acting as joint book-running managers, with Baird as lead manager. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Impact on assets 3

Financials▲ · 2 stocks
Biotech & Genomic Medicine▼ · 1 stocks

Off-coverage companies 1

Robert W. Baird & Co. IncorporatedPrivate± Mixed
relevance

© 2026 MarketIVNews